Results 31 to 40 of about 36,553 (257)

Evaluation of immunogenicity-induced DNA vaccines against different SARS-CoV-2 variants.

PLoS ONE, 2023
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged in 2019 and caused the coronavirus disease 2019 (COVID-19) pandemic worldwide. As of September 2023, the number of confirmed coronavirus cases has reached over 770 million and caused ...
Se Eun Kim, So Hee Park, Woo-Jung Park, Gayeong Kim, Seo Yeon Kim, Hyeran Won, Yun-Ho Hwang, Heeji Lim, Hyeon Guk Kim, You-Jin Kim, Dokeun Kim, Jung-Ah Lee   +11 more
doaj   +1 more source

Dynamics of humoral and cellular immune responses after homologous and heterologous SARS-CoV-2 vaccination with ChAdOx1 nCoV-19 and BNT162b2

EBioMedicine, 2022
Summary: Background: Vaccines are an important means to overcome the SARS-CoV-2 pandemic. They induce specific antibody and T-cell responses but it remains open how well vaccine-induced immunity is preserved over time following homologous and ...
Emanuel Vogel, Katharina Kocher, Alina Priller, Cho-Chin Cheng, Philipp Steininger, Bo-Hung Liao, Nina Körber, Annika Willmann, Pascal Irrgang, Jürgen Held, Carolin Moosmann, Viviane Schmidt, Stephanie Beileke, Monika Wytopil, Sarah Heringer, Tanja Bauer, Ronja Brockhoff, Samuel Jeske, Hrvoje Mijocevic, Catharina Christa, Jon Salmanton-García, Kathrin Tinnefeld, Christian Bogdan, Sarah Yazici, Percy Knolle, Oliver A. Cornely, Klaus Überla, Ulrike Protzer, Kilian Schober, Matthias Tenbusch   +29 more
doaj   +1 more source

Reactogenicity and Humoral Immune Response after Heterologous Vaxzevria/Comirnaty Vaccination in a Group of Individuals Vaccinated in the AOU Policlinic “G. Martino” (Messina, Italy): A Retrospective Cohort Study

Vaccines, 2022
On 11 June 2021, the Italian Ministry of Health authorized the heterologous vaccination schedule. The goals of our retrospective study were to (a) evaluate the undesirable effects after the administration of Vaxzevria and Comirnaty vaccines; (b) evaluate
Roberto Venuto, Ioselita Giunta, Mario Vaccaro, Vincenza La Fauci, Concetta Ceccio, Francesco Fedele, Antonino Privitera, Federica Denaro, Giuseppe Pantò, Rosaria Cortese, Giovanna Visalli, Smeralda D’Amato, Andrea Squeri, Raffaele Squeri, Cristina Genovese   +14 more
doaj   +1 more source

H5N1 Protection by Seasonal Influenza Vaccine in Homologous and Heterologous Prime/Boost Vaccination

Journal of Vaccines & Vaccination, 2015
Background A number of different approaches aimed at broadening the cross-protective ability of seasonal influenza vaccines are being explored today. Priming a seasonal vaccine with three administrations of DNA encoding H1 HA corresponding to the HA in the seasonal vaccine has been shown to confer protection against heterologous H1N1 influenza.
Roos A, Roozendaal R
openaire   +1 more source

Omicron variant showed lower neutralizing sensitivity than other SARS-CoV-2 variants to immune sera elicited by vaccines after boost

Emerging Microbes and Infections, 2022
The emerging new VOC B.1.1.529 (Omicron) variant has raised serious concerns due to multiple mutations, reported significant immune escape, and unprecedented rapid spreading speed.
Jingwen Ai, Haocheng Zhang, Yi Zhang, Ke Lin, Yanliang Zhang, Jing Wu, Yanming Wan, Yanfang Huang, Jieyu Song, Zhangfan Fu, Hongyu Wang, Jingxin Guo, Ning Jiang, Mingxiang Fan, Yang Zhou, Yuanhan Zhao, Qiran Zhang, Qiang Liu, Jing Lv, Peiyao Li, Chao Qiu, Wenhong Zhang   +21 more
doaj   +1 more source

Heterologous prime-boost vaccination with DNA and MVA vaccines, expressing HIV-1 subtype C mosaic Gag virus-like particles, is highly immunogenic in mice. [PDF]

PLoS ONE, 2017
In an effort to make affordable vaccines suitable for the regions most affected by HIV-1, we have constructed stable vaccines that express an HIV-1 subtype C mosaic Gag immunogen (BCG-GagM, MVA-GagM and DNA-GagM).
Ros Chapman, Tsungai Ivai Jongwe, Nicola Douglass, Gerald Chege, Anna-Lise Williamson   +4 more
doaj   +1 more source

Differences in Immunogenicity of Three Different Homo- and Heterologous Vaccination Regimens against SARS-CoV-2

Vaccines, 2022
Background: Due to findings on adverse reactions and clinical efficacy of different vaccinations against SARS-CoV-2, the administration of vaccination regimens containing both adenoviral vector vaccines and mRNA-based vaccines has become common. Data are
Robert Daniel Heinrich Markewitz, David Juhl, Daniela Pauli, Siegfried Görg, Ralf Junker, Jan Rupp, Sarah Engel, Katja Steinhagen, Victor Herbst, Dorinja Zapf, Christina Krüger, Christian Brockmann, Frank Leypoldt, Justina Dargvainiene, Benjamin Schomburg, Shahpour Reza Sharifzadeh, Lukas Salek Nejad, Klaus-Peter Wandinger, Malte Ziemann   +18 more
doaj   +1 more source

Protectivity of COVID-19 Vaccines and Its Relationship with Humoral Immune Response and Vaccination Strategy: A One-Year Cohort Study

Vaccines, 2022
This prospective cohort study aimed to evaluate the efficacy of COVID-19 vaccine schemes, homologous versus heterologous vaccine strategies, and vaccine-induced anti-S-RBD-IgG antibody response in preventing COVID-19 among 942 healthcare workers 1 year ...
Ferdi Tanir, Burak Mete, Hakan Demirhindi, Ertan Kara, Ersin Nazlican, Gülçin Dağlıoğlu, Filiz Kibar, Salih Çetiner, Ceren Kanat   +8 more
doaj   +1 more source

Leukocytic and Pyrogenic Effects of Typhoid Vaccine and Augmentation by Homologous Plasma

Experimental Biology and Medicine, 1950
Summary and ConclusionsThe effects of intravenously administered typhoid vaccine upon the leukocyte population and the temperature of the rabbit were studied.The response of the temperature and of the leukocyte count was dependent upon the amount of typhoid vaccine given.
R S, FARR, V S, LeQUIRE
openaire   +2 more sources

Immunogenicity and reactogenicity of a heterologous COVID-19 prime-boost vaccination compared with homologous vaccine regimens [PDF]

, 2021
Abstract Heterologous priming with the ChAdOx1-nCoV-19 vector-vaccine followed by boosting with an mRNA-vaccine is currently recommended in Germany, although data on immunogenicity and reactogenicity are not available. Here we show that the heterologous regimen induced spike-specific IgG, neutralizing antibodies, and spike-specific CD4 ...
Tina Schmidt, Verena Klemis, David Schub, Janine Mihm, Franziska Hielscher, Stefanie Marx, Amina Abu-Omar, Sophie Schneitler, Sören L. Becker, Barbara C. Gärtner, Urban Sester, Martina Sester   +11 more
openaire   +1 more source